Kuehn Law is investigating whether officers and directors of Regenxbio, Inc. breached fiduciary duties by providing false or misleading information about the efficacy and safety of RGX-111, a gene therapy for Hurler Syndrome. The firm is seeking shareholders who purchased stock prior to February 9, 2022.

A comprehensive pipeline analysis reveals over 50 companies developing 55+ drugs for diabetic retinopathy treatment. Key developments include Kodiak Sciences' Tarcocimab tedromer (Phase III anti-VEGF therapy), Vantage Biosciences' VX-01 (Phase II oral treatment), and Therini Bio's THN391 (Phase I fibrin-targeting therapy). The report covers therapeutic assessments across various development stages, routes of administration, and molecule types, highlighting emerging opportunities in retinal disease treatment.

DelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Phase IIb/III trial initiation for MK-8748, 4D Molecular Therapeutics' Phase III enrollment completion for 4D-150, and FDA fast-track designation for SAR402663.

REGENXBIO Inc. (NASDAQ: RGNX) faces a class action lawsuit for securities violations. The company allegedly made false and misleading statements about the safety and efficacy of its RGX-111 product candidate while concealing adverse information from investors. The FDA placed a clinical hold on RGX-111 after a clinical trial participant developed a tumor. Shareholders who purchased shares between February 9, 2022 and January 27, 2026 are encouraged to contact DJS Law Group regarding potential recovery.

Pomerantz Law Firm has filed class action lawsuits against REGENXBIO Inc., AMC Entertainment Holdings, Inc., and Upstart Holdings, Inc. for alleged securities fraud and unlawful business practices. The REGENXBIO lawsuit was triggered by an FDA clinical hold on its gene therapy candidates RGX-111 and RGX-121, which caused the stock to fall 17.9% on January 28, 2026. Investors with losses are urged to contact the firm by the April 14, 2026 deadline to potentially serve as lead plaintiff.

Pomerantz Law Firm has filed class action lawsuits against AMC Entertainment Holdings, REGENXBIO Inc., and Upstart Holdings, alleging securities fraud and unlawful business practices. The AMC lawsuit specifically concerns APE preferred equity unit holders who were excluded from a special dividend following conversion to common stock due to an undisclosed loophole in the Certificate of Designations. Investors have until April 20, 2026, to request Lead Plaintiff status.

REGENXBIO investors can file a class action lawsuit for securities purchased between February 9, 2022 and January 27, 2026. The lawsuit alleges the company made false statements about the safety and efficacy of its RGX-111 gene therapy. On January 28, 2026, REGENXBIO announced the FDA placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a trial participant, causing the stock to fall nearly 18%.

Rosen Law Firm is reminding REGENXBIO investors who purchased securities between February 9, 2022 and January 27, 2026 of the April 14, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements about the efficacy and safety of its RGX-111 gene therapy trial while providing overwhelmingly positive public assertions, resulting in investor damages.

A class action lawsuit has been filed against REGENXBIO Inc. alleging that the company made materially false and misleading statements regarding its RGX-111 gene therapy development and clinical trial results. The lawsuit covers investors who purchased securities between February 9, 2022 and January 27, 2026, with a lead plaintiff deadline of April 14, 2026.

The Schall Law Firm is seeking lead plaintiffs for a securities fraud class action lawsuit against REGENXBIO Inc. The lawsuit alleges the company made false and misleading statements about its product candidate RGX-111, concealing negative efficacy and safety data while presenting overwhelmingly positive statements to investors. The fraud was allegedly revealed when an intraventricular CNS tumor was discovered in a study participant. Investors who purchased securities between February 9, 2022 and January 27, 2026 are encouraged to join the case.

A securities class action lawsuit has been filed against REGENXBIO, Inc. for allegedly providing materially false and misleading statements regarding the efficacy and safety of its RGX-111 gene therapy trial while making positive assertions to investors. The firm is seeking a lead plaintiff by April 14, 2026, for investors who purchased securities between February 9, 2022 and January 27, 2026.

Rosen Law Firm is notifying investors in BlackRock TCP Capital Corp. (TCPC) and other companies about ongoing securities class action lawsuits. The firm is seeking a lead plaintiff by the April 6, 2026 deadline. According to the lawsuit, BlackRock TCP made materially false statements regarding investment valuations, portfolio quality, and net asset value, resulting in investor losses.